ES2721656T3 - Anticuerpo anti-CD19 que tiene función ADCC con un perfil de glicosilación mejorado - Google Patents

Anticuerpo anti-CD19 que tiene función ADCC con un perfil de glicosilación mejorado Download PDF

Info

Publication number
ES2721656T3
ES2721656T3 ES11736051T ES11736051T ES2721656T3 ES 2721656 T3 ES2721656 T3 ES 2721656T3 ES 11736051 T ES11736051 T ES 11736051T ES 11736051 T ES11736051 T ES 11736051T ES 2721656 T3 ES2721656 T3 ES 2721656T3
Authority
ES
Spain
Prior art keywords
antibody
replaced
amino acid
leu
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11736051T
Other languages
English (en)
Inventor
Gilles Salles
Claudine Vermot-Desroches
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Int Drug Development Biotech
Universite Claude Bernard Lyon 1 UCBL
Hospices Civils de Lyon HCL
International Drug Development Biotech SAS
Original Assignee
Int Drug Development Biotech
Universite Claude Bernard Lyon 1 UCBL
Hospices Civils de Lyon HCL
International Drug Development Biotech SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Drug Development Biotech, Universite Claude Bernard Lyon 1 UCBL, Hospices Civils de Lyon HCL, International Drug Development Biotech SAS filed Critical Int Drug Development Biotech
Application granted granted Critical
Publication of ES2721656T3 publication Critical patent/ES2721656T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un anticuerpo anti-CD19 modificado para comprender una región Fc de IgG1 humana variable, donde esta región variable comprende modificaciones que consisten en una sustitución de aminoácido en cada una de las posiciones de aminoácidos Phe243, Arg292, Tyr300, Val305 y Pro396 de la región Fc de IgG1 Fc humana, donde la numeración de los residuos de aminoácidos en la región Fc es la de Kabat, donde el anticuerpo ha sido producido en células de roedor de tipo salvaje, donde: Phe243 se sustituye por Leu, Arg292 se sustituye por Pro, Tyr300 se sustituye por Leu, Val305 se sustituye por Leu, Pro396 se sustituye por Leu, donde el anticuerpo comprende la secuencia de aminoácidos de VH SEQ ID NO: 27 y la secuencia de aminoácidos de VL SEQ ID NO: 29, y donde el anticuerpo tiene función de ADCC pero no tiene función de CDC y desencadena la muerte celular programada.
ES11736051T 2010-07-19 2011-07-18 Anticuerpo anti-CD19 que tiene función ADCC con un perfil de glicosilación mejorado Active ES2721656T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36556910P 2010-07-19 2010-07-19
EP20100305797 EP2409993A1 (en) 2010-07-19 2010-07-19 Anti-CD19 antibody having ADCC function with improved glycosylation profile
PCT/EP2011/062270 WO2012010561A1 (en) 2010-07-19 2011-07-18 Anti-cd19 antibody having adcc function with improved glycosylation profile

Publications (1)

Publication Number Publication Date
ES2721656T3 true ES2721656T3 (es) 2019-08-02

Family

ID=43587158

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11736051T Active ES2721656T3 (es) 2010-07-19 2011-07-18 Anticuerpo anti-CD19 que tiene función ADCC con un perfil de glicosilación mejorado

Country Status (5)

Country Link
US (1) US9120856B2 (es)
EP (2) EP2409993A1 (es)
DK (1) DK2596024T3 (es)
ES (1) ES2721656T3 (es)
WO (1) WO2012010561A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
LT3302550T (lt) 2015-05-26 2019-11-11 Morphosys Ag Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas
RS62260B1 (sr) 2015-08-21 2021-09-30 Morphosys Ag Kombinacije i njihova upotreba
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
PE20181089A1 (es) * 2015-10-02 2018-07-09 Hoffmann La Roche Anticuerpos anti-cd19 humano con alta afinidad
WO2017066136A2 (en) * 2015-10-13 2017-04-20 Eureka Therapeutics, Inc. Antibody agents specific for human cd19 and uses thereof
EP3465214B1 (en) 2016-05-30 2021-04-28 MorphoSys AG Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
US11352423B2 (en) 2016-06-27 2022-06-07 Morphosys Ag Anti-CD19 antibody formulations
CN109890418B (zh) 2016-10-28 2024-03-08 莫佛塞斯公司 抗cd19抗体与bcl-2抑制剂的组合及其用途
WO2019011918A1 (en) 2017-07-10 2019-01-17 International - Drug - Development - Biotech TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS
BR112020005402A2 (pt) * 2017-09-21 2020-09-29 WuXi Biologics Ireland Limited anticorpos, sequências de polinucleotídeo e de ácido nucleico, vetores, célula hospedeira, métodos de expressar o anticorpo e de modulação conjugado, composição farmacêutica, métodos para tratar uma doença, para detectar, para diagnosticar e para estimular uma resposta imune, método in vivo ou in vitro, uso, receptor de antígeno quimérico e célula t
AU2020267823A1 (en) 2019-05-03 2021-11-11 Incyte Corporation Anti-CD19 therapy in patients having a limited number of NK cells
WO2021067598A1 (en) 2019-10-04 2021-04-08 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
CN114641312A (zh) 2019-10-31 2022-06-17 莫佛塞斯公司 抗cd19疗法与来那度胺组合用于治疗白血病或淋巴瘤
WO2021084063A1 (en) 2019-10-31 2021-05-06 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
CN115956088A (zh) 2020-06-22 2023-04-11 莫佛塞斯公司 包括抗-CD19抗体和阻断SIRPα-CD47先天免疫检查点的多肽的抗肿瘤组合疗法
JP2023544200A (ja) 2020-10-06 2023-10-20 ゼンコー・インコーポレイテッド 全身性エリテマトーデス（ｓｌｅ）を含む自己免疫疾患を治療するためのバイオマーカー、方法、及び組成物
EP4255480A2 (en) 2020-12-04 2023-10-11 MorphoSys AG Anti-cd19 combination therapy
WO2023073645A1 (en) 2021-10-29 2023-05-04 Takeda Pharmaceutical Company Limited Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
WO2024038115A1 (en) 2022-08-17 2024-02-22 Morphosys Ag Therapy comprising anti-cd19 antibody and ezh2 modulators

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
WO1991013974A1 (en) 1990-03-14 1991-09-19 The Biomembrane Institute Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
JPH11505704A (ja) 1995-05-17 1999-05-25 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ アンチｃｄ−１９抗体の単鎖可変領域フラグメントを含む免疫コンジュゲート
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1068241E (pt) 1998-04-02 2007-11-19 Genentech Inc Variantes de anticorpos e respectivos fragmentos
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
US20060257399A1 (en) * 2000-06-28 2006-11-16 Glycofi, Inc. Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20040136908A1 (en) 2001-04-09 2004-07-15 Olson William C. Anti-cd19 immunotoxins
MXPA04001072A (es) 2001-08-03 2005-02-17 Glycart Biotechnology Ag Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada.
CN1200030C (zh) 2002-02-05 2005-05-04 复旦大学 一步法制备结构稳定、高浓度且具有核－壳结构的聚合物纳米胶束
JP2008501621A (ja) 2003-05-31 2008-01-24 マイクロメット アクツィエン ゲゼルシャフト Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
WO2005012493A2 (en) 2003-07-31 2005-02-10 Immunomedics, Inc. Anti-cd19 antibodies
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
FR2861080B1 (fr) 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
CA2544865C (en) 2003-11-05 2019-07-09 Glycart Biotechnology Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
DK1817055T3 (da) * 2004-11-10 2013-04-08 Diadexus Inc Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse heraf
CA2587766A1 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
EP1909848A2 (en) 2005-08-01 2008-04-16 PSivida Inc. HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF
DK2270050T3 (da) 2005-12-30 2013-08-12 Merck Patent Gmbh Anti-CD19-antistoffer med nedsat immunogenicitet
US20070166306A1 (en) 2006-01-17 2007-07-19 Fey Georg H M Anti-CD19 antibody composition and method
JP2009529331A (ja) 2006-03-10 2009-08-20 マクロジェニクス，インコーポレーテッド 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
AU2007285976B2 (en) 2006-08-14 2011-08-18 Xencor, Inc Optimized antibodies that target CD19
MX2009002414A (es) 2006-09-08 2009-05-20 Medimmune Llc Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria.
US8652466B2 (en) * 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
US7968687B2 (en) 2007-10-19 2011-06-28 Seattle Genetics, Inc. CD19 binding agents and uses thereof

Also Published As

Publication number Publication date
EP2596024B1 (en) 2018-12-26
EP2409993A1 (en) 2012-01-25
DK2596024T3 (en) 2019-04-15
US20130183306A1 (en) 2013-07-18
EP2596024A1 (en) 2013-05-29
US9120856B2 (en) 2015-09-01
WO2012010561A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
ES2721656T3 (es) Anticuerpo anti-CD19 que tiene función ADCC con un perfil de glicosilación mejorado
CY1125092T1 (el) Ιατρικη χρηση σχετικα με επεκταση τελομερους
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
AR070315A1 (es) Anticuerpos 1b20 antagonistas de pcsk9
CL2016003096A1 (es) Métodos para cosechar cultivos de células de mamífero
CL2022001375A1 (es) Receptores de antígeno quimérico cd19 y cd22 y usos de los mismos
AR088941A1 (es) Anticuerpos anti-fgfr2 y sus usos
PE20110802A1 (es) Un anticuerpo antagonista de pcsk9
TR201903439T4 (tr) İnsanlaştırılmış hafif zincirli fareler.
PE20190510A1 (es) Anticuerpos anti-pd-l1 y usos de los mismos
ES2721753T3 (es) Anticuerpos contra IL-6 y usos de los mismos
WO2013144566A3 (en) Animals expressing human lambda immunoglobulin light chain variable domain
ECSP099379A (es) Anticuerpos anti-factor d humanizados
PA8672101A1 (es) Anticuerpos anti-il-6, composiciones, métodos y usos
AR102888A1 (es) Animales no humanos que tienen un gen humanizado de agrupamiento de diferenciación 47
PE20081478A1 (es) Anticuerpos cd44
AR089393A1 (es) Composiciones y metodos para anticuerpos que actuan sobre el factor p
CO2018002265A2 (es) Anticuerpos anti-cd19 humano humanizados
ES2721882T3 (es) Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
MX2012015300A (es) Ratones que expresan una cadena ligera con regiones constantes de raton y variables lambda humanas.
SMT201300046B (it) Modelli animali e molecole terapeutiche
ECSP109946A (es) Anticuerpos Anti-CD37
CU20120116A7 (es) Polipéptidos que se enlazan a dr5 humana con efectos agonistas, que comprenden uno o más monómeros de un único dominio variable, utiles en el tratamiento de enfermedades y trastornos asociados con dr5
GT201300306A (es) Anticuerpos anti-angptl3 y usos de los mismos
NZ630637A (en) Common light chain mouse